181 related articles for article (PubMed ID: 29246694)
1. Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen.
Cheuk-Fung Yip T; Wai-Sun Wong V; Lik-Yuen Chan H; Tse YK; Pik-Shan Kong A; Long-Yan Lam K; Chung-Yan Lui G; Lai-Hung Wong G
Clin Gastroenterol Hepatol; 2018 May; 16(5):765-773.e2. PubMed ID: 29246694
[TBL] [Abstract][Full Text] [Related]
2. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
[TBL] [Abstract][Full Text] [Related]
3. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL
J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985
[TBL] [Abstract][Full Text] [Related]
5. CAMP-B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance.
Lee HW; Yip TC; Wong VW; Lim YS; Chan HL; Ahn SH; Wong GL; Choi J
Aliment Pharmacol Ther; 2024 May; 59(10):1223-1235. PubMed ID: 38425096
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
[TBL] [Abstract][Full Text] [Related]
7. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
[TBL] [Abstract][Full Text] [Related]
8. Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
Yip TC; Wong VW; Tse YK; Liang LY; Hui VW; Zhang X; Li GL; Lui GC; Chan HL; Wong GL
Aliment Pharmacol Ther; 2021 Jan; 53(2):321-331. PubMed ID: 33222272
[TBL] [Abstract][Full Text] [Related]
9. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
[TBL] [Abstract][Full Text] [Related]
10. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
[TBL] [Abstract][Full Text] [Related]
11. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
[TBL] [Abstract][Full Text] [Related]
12. Coexistence of hepatitis B surface antigen and antibody to hepatitis B surface may increase the risk of hepatocellular carcinoma in chronic hepatitis B virus infection: a retrospective cohort study.
Seo SI; Choi HS; Choi BY; Kim HS; Kim HY; Jang MK
J Med Virol; 2014 Jan; 86(1):124-30. PubMed ID: 24127328
[TBL] [Abstract][Full Text] [Related]
13. Enhancers and attenuators of risk associations of chronic hepatitis B virus infection with hepatocellular carcinoma in type 2 diabetes.
Yang X; Wang Y; Luk AO; So WY; Ma RC; Kong AP; Xu G; Chan JC
Endocr Relat Cancer; 2013 Apr; 20(2):161-71. PubMed ID: 23250907
[TBL] [Abstract][Full Text] [Related]
14. Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis.
Yang HI; Tseng TC; Liu J; Lee MH; Liu CJ; Su TH; Batrla-Utermann R; Chan HL; Kao JH; Chen CJ
Clin Gastroenterol Hepatol; 2016 Mar; 14(3):461-468.e2. PubMed ID: 26598229
[TBL] [Abstract][Full Text] [Related]
15. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.
Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL
Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377
[TBL] [Abstract][Full Text] [Related]
16. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
[TBL] [Abstract][Full Text] [Related]
17. Elevated testosterone increases risk of hepatocellular carcinoma in men with chronic hepatitis B and diabetes mellitus.
Yip TC; Wong GL; Chan HL; Tse YK; Liang LY; Hui VW; Lee HW; Lui GC; Kong AP; Wong VW
J Gastroenterol Hepatol; 2020 Dec; 35(12):2210-2219. PubMed ID: 32343449
[TBL] [Abstract][Full Text] [Related]
18. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance.
Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD
Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732
[TBL] [Abstract][Full Text] [Related]
19. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
Yoo S; Kim JY; Lim YS; Han S; Choi J
J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206
[TBL] [Abstract][Full Text] [Related]
20. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance.
Cheung KS; Mak LY; Lam LK; Fung J; Liu F; Seto WK; Yuen MF
Hepatol Int; 2021 Aug; 15(4):881-891. PubMed ID: 33988834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]